Sarcoma News

The antitumor drug trabectedin demonstrated superior disease control compared with conventional chemotherapy among patients with advanced liposarcoma and leiomyosarcoma who failed after prior chemotherapy, according to the results of a phase 3 randomized controlled trial.

Amid the myriad concerns that accompany a cancer diagnosis, the risk for venous thromboembolism may be last on the minds of patients and clinicians.

Two studies published in JAMA Oncology focused on the long-term hospitalization risks and neurocognitive outcomes of survivors of adolescent and young adult cancers.

Family history of cancer did not predict the presence of an underlying predisposition syndrome in a majority of pediatric patients with cancer, according to study results published in The New England Journal of Medicine.

A set of genes involved in CXC4-pathway signaling appeared to serve as a positive marker for OS and EFS and a negative marker for metastases development among patients with Ewing’s sarcoma, according to study results.

Investigators found a union rate of 90% and an average Musculoskeletal Tumor Society score of 89.3% in a minimum 2-year follow-up of patients with sarcoma or cancer who were treated with frozen autograft-prosthesis composite reconstruction.

I have had the privilege of taking care of many young adult patients with lymphomas.

Cancer survivorship care has always been and continues to be an extension of good cancer care.

Photodynamic therapy is a targeted cancer therapy that administers a nontoxic drug that settles in tumor cells and is followed by the application of laser light to the tumor.

The FDA has granted breakthrough therapy designation to the oral CSF-1R inhibitor pexidartinib for the treatment of tenosynovial giant cell tumor that cannot be surgically removed due to the risks for worsening functional limitation or severe morbidity, according to a press release from the drug’s manufacturer.